Ivermectin
- The Panel recommends against the use of ivermectin for the treatment of COVID-19, except in a clinical trial (AIII).
|
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies; III = Expert opinion |
To pravi NIH... Pravi prav tako:
However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected
in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.
In še:
Ivermectin is not approved for the treatment of any viral infection, including SARS-CoV-2 infection. The FDA issued a
warning in April 2020 that ivermectin intended for use in animals should not be used to treat COVID-19 in humans.